Reports Q1 product revenue $2.21M vs $2.35M last year. Mytesi prescription volume increased by approximately 1.8% in Q1 2025 over Q1 2024 and decreased by approximately 13.5% in Q1 2025 over Q4 2024.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Health Highlights Promising Crofelemer Study Results
- Jaguar Health provides overview of 2025 crofelemer-related catalysts
- Jaguar Health’s Napo reports initial PoC results from trial of crofelemer
- Jaguar Health Announces Promising Crofelemer Trial Results
- Biotech Alert: Searches spiking for these stocks today
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue